SK Biopharmaceuticals announced its bold vision of becoming one of the top 10 players in the global healthcare market by 2030.
Under the vision dubbed “Financial Story”, the Korean company aims to strengthen its leadership in the area of neurological diseases by launching new products in the U.S. and to secure competitiveness by expanding pipelines in global markets.
In Europe and Asia, the company said it will develop several business models through strategic partnerships.
It will also look for first-in-class drugs in wider therapeutic areas range beyond central nervous system diseases with a focus on four major disease groups: epilepsy, rare neurological diseases, mental disorders, and cancer.
It also plans to speed up the drug discovery and development processes by using artificial intelligence, digital transformation and cutting-edge RNA technology.
SK Biopharmaceuticals will also publish a sustainability report as part of environmental, social, and governance (ESG) disclosure practices. In line with SK Group’s vision, the company also set a goal of achieving carbon neutrality by 2040.
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]